Cargando…

A 3D Human Liver Model of Nonalcoholic Steatohepatitis

Background and Aims: To better understand nonalcoholic steatohepatitis (NASH) disease progression and to evaluate drug targets and compound activity, we undertook the development of an in vitro 3D model to mimic liver architecture and the NASH environment. Methods: We have developed an in vitro prec...

Descripción completa

Detalles Bibliográficos
Autores principales: Duriez, Marion, Jacquet, Agnes, Hoet, Lucile, Roche, Sandrine, Bock, Marie-Dominique, Rocher, Corinne, Haussy, Gilles, Vigé, Xavier, Bocskei, Zsolt, Slavnic, Tamara, Martin, Valérie, Guillemot, Jean-Claude, Didier, Michel, Kannt, Aimo, Orsini, Cécile, Mikol, Vincent, Fèvre, Anne-Céline Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782122/
https://www.ncbi.nlm.nih.gov/pubmed/33447518
http://dx.doi.org/10.14218/JCTH.2020.00015
_version_ 1783631828691714048
author Duriez, Marion
Jacquet, Agnes
Hoet, Lucile
Roche, Sandrine
Bock, Marie-Dominique
Rocher, Corinne
Haussy, Gilles
Vigé, Xavier
Bocskei, Zsolt
Slavnic, Tamara
Martin, Valérie
Guillemot, Jean-Claude
Didier, Michel
Kannt, Aimo
Orsini, Cécile
Mikol, Vincent
Fèvre, Anne-Céline Le
author_facet Duriez, Marion
Jacquet, Agnes
Hoet, Lucile
Roche, Sandrine
Bock, Marie-Dominique
Rocher, Corinne
Haussy, Gilles
Vigé, Xavier
Bocskei, Zsolt
Slavnic, Tamara
Martin, Valérie
Guillemot, Jean-Claude
Didier, Michel
Kannt, Aimo
Orsini, Cécile
Mikol, Vincent
Fèvre, Anne-Céline Le
author_sort Duriez, Marion
collection PubMed
description Background and Aims: To better understand nonalcoholic steatohepatitis (NASH) disease progression and to evaluate drug targets and compound activity, we undertook the development of an in vitro 3D model to mimic liver architecture and the NASH environment. Methods: We have developed an in vitro preclinical 3D NASH model by coculturing primary human hepatocytes, human stellate cells, liver endothelial cells and Kupffer cells embedded in a hydrogel of rat collagen on a 96-well plate. A NASH-like environment was induced by addition of medium containing free fatty acids and tumor necrosis factor-α. This model was then characterized by biochemical, imaging and transcriptomics analyses. Results: We succeeded in defining suitable culture conditions to maintain the 3D coculture for up to 10 days in vitro, with the lowest level of steatosis and reproducible low level of inflammation and fibrosis. NASH disease was induced with a custom medium mimicking NASH features. The cell model exhibited the key NASH disease phenotypes of hepatocyte injury, steatosis, inflammation, and fibrosis. Hepatocyte injury was highlighted by a decrease of CYP3A4 expression and activity, without loss of viability up to day 10. Moreover, the model was able to stimulate a stable inflammatory and early fibrotic environment, with expression and secretion of several cytokines. A global gene expression analysis confirmed the NASH induction. Conclusions: This is a new in vitro model of NASH disease consisting of four human primary cell-types that exhibits most features of the disease. The 10-day cell viability and cost effectiveness of the model make it suitable for medium throughput drug screening and provide attractive avenues to better understand disease physiology and to identify and characterize new drug targets.
format Online
Article
Text
id pubmed-7782122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-77821222021-01-13 A 3D Human Liver Model of Nonalcoholic Steatohepatitis Duriez, Marion Jacquet, Agnes Hoet, Lucile Roche, Sandrine Bock, Marie-Dominique Rocher, Corinne Haussy, Gilles Vigé, Xavier Bocskei, Zsolt Slavnic, Tamara Martin, Valérie Guillemot, Jean-Claude Didier, Michel Kannt, Aimo Orsini, Cécile Mikol, Vincent Fèvre, Anne-Céline Le J Clin Transl Hepatol Original Article Background and Aims: To better understand nonalcoholic steatohepatitis (NASH) disease progression and to evaluate drug targets and compound activity, we undertook the development of an in vitro 3D model to mimic liver architecture and the NASH environment. Methods: We have developed an in vitro preclinical 3D NASH model by coculturing primary human hepatocytes, human stellate cells, liver endothelial cells and Kupffer cells embedded in a hydrogel of rat collagen on a 96-well plate. A NASH-like environment was induced by addition of medium containing free fatty acids and tumor necrosis factor-α. This model was then characterized by biochemical, imaging and transcriptomics analyses. Results: We succeeded in defining suitable culture conditions to maintain the 3D coculture for up to 10 days in vitro, with the lowest level of steatosis and reproducible low level of inflammation and fibrosis. NASH disease was induced with a custom medium mimicking NASH features. The cell model exhibited the key NASH disease phenotypes of hepatocyte injury, steatosis, inflammation, and fibrosis. Hepatocyte injury was highlighted by a decrease of CYP3A4 expression and activity, without loss of viability up to day 10. Moreover, the model was able to stimulate a stable inflammatory and early fibrotic environment, with expression and secretion of several cytokines. A global gene expression analysis confirmed the NASH induction. Conclusions: This is a new in vitro model of NASH disease consisting of four human primary cell-types that exhibits most features of the disease. The 10-day cell viability and cost effectiveness of the model make it suitable for medium throughput drug screening and provide attractive avenues to better understand disease physiology and to identify and characterize new drug targets. XIA & HE Publishing Inc. 2020-12-15 2020-12-28 /pmc/articles/PMC7782122/ /pubmed/33447518 http://dx.doi.org/10.14218/JCTH.2020.00015 Text en © 2020 Authors. http://creativecommons.org/licenses/by-nc/4.0/ This article has been published under the terms of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. “This article has been published in Journal of Clinical and Translational Hepatology at DOI: 10.14218/JCTH.2020.00015 and can also be viewed on the Journal’s website at http://www.jcthnet.com”.
spellingShingle Original Article
Duriez, Marion
Jacquet, Agnes
Hoet, Lucile
Roche, Sandrine
Bock, Marie-Dominique
Rocher, Corinne
Haussy, Gilles
Vigé, Xavier
Bocskei, Zsolt
Slavnic, Tamara
Martin, Valérie
Guillemot, Jean-Claude
Didier, Michel
Kannt, Aimo
Orsini, Cécile
Mikol, Vincent
Fèvre, Anne-Céline Le
A 3D Human Liver Model of Nonalcoholic Steatohepatitis
title A 3D Human Liver Model of Nonalcoholic Steatohepatitis
title_full A 3D Human Liver Model of Nonalcoholic Steatohepatitis
title_fullStr A 3D Human Liver Model of Nonalcoholic Steatohepatitis
title_full_unstemmed A 3D Human Liver Model of Nonalcoholic Steatohepatitis
title_short A 3D Human Liver Model of Nonalcoholic Steatohepatitis
title_sort 3d human liver model of nonalcoholic steatohepatitis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782122/
https://www.ncbi.nlm.nih.gov/pubmed/33447518
http://dx.doi.org/10.14218/JCTH.2020.00015
work_keys_str_mv AT duriezmarion a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT jacquetagnes a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT hoetlucile a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT rochesandrine a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT bockmariedominique a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT rochercorinne a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT haussygilles a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT vigexavier a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT bocskeizsolt a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT slavnictamara a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT martinvalerie a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT guillemotjeanclaude a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT didiermichel a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT kanntaimo a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT orsinicecile a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT mikolvincent a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT fevreannecelinele a3dhumanlivermodelofnonalcoholicsteatohepatitis
AT duriezmarion 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT jacquetagnes 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT hoetlucile 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT rochesandrine 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT bockmariedominique 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT rochercorinne 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT haussygilles 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT vigexavier 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT bocskeizsolt 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT slavnictamara 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT martinvalerie 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT guillemotjeanclaude 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT didiermichel 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT kanntaimo 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT orsinicecile 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT mikolvincent 3dhumanlivermodelofnonalcoholicsteatohepatitis
AT fevreannecelinele 3dhumanlivermodelofnonalcoholicsteatohepatitis